Business & Industry News Channel

Boehringer Ingelheim expands development capacities with new technical centre

2012-05-31T21:00:00Z

The research driven pharmaceutical company Boehringer Ingelheim is establishing a new 50 million-plus euro pilot plant facility for the production of newly developed active pharmaceutical ingredients. The company announced this investment in its largest research and development site worldwide in Biberach, Germany.

UCB expands in Brazil

2012-05-30T21:00:01Z

UCB (Euronext Brussels: UCB) and Meizler Biopharma, a privately-owned Brazilian pharmaceutical company, have signed an agreement by which UCB acquires 51% of Meizler Biopharma. The agreement foresees performance related milestone payments in the coming years as well as an option to purchase the remaining 49% later in time.

Genzyme recognizes World MS Day

2012-05-30T21:00:00Z

Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), marked World MS Day with activities across its global network and new programs designed to mobilize and inspire people living with multiple sclerosis.

Bristol-Myers Squibb announces global collaboration with leading academic institutions

2012-05-29T21:00:00Z

Bristol-Myers Squibb Company (NYSE: BMY) announced the formation of the International Immuno-Oncology Network (II-ON), a global collaboration between industry and academia that aims to further the scientific understanding of immuno-oncology.

Lundbeck's Lu AE58054 meets primary endpoint

2012-05-29T09:00:00Z

H. Lundbeck A/S (Lundbeck) today announced that Lu AE58054 has met its primary endpoint in a fixed dose, randomized, placebo-controlled clinical study in 278 patients suffering from Alzheimer's disease.

Innovative public-private collaboration launches to tackle antibiotic research

2012-05-24T21:00:00Z

GlaxoSmithKline and AstraZeneca welcomed the launch of a pioneering approach to antibiotic research in Europe that will see pharmaceutical and biotechnology companies working alongside public partners to tackle the rising threat from antibiotic resistance and address some of the key barriers to the development of effective antibiotics.

Bayer's Regorafenib submitted for EU and US marketing authorization

2012-05-23T21:00:00Z

Bayer HealthCare has submitted a Marketing Authorization Application to the European Medicines Agency (EMA) and a New Drug Application to the U.S. Food and Drug Administration (FDA) for the oral multi-kinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer (mCRC).

One million signatures needed to call upon World Health Organisation

2012-05-22T21:00:00Z

The 1 Mission 1 Million - Getting to the Heart of Stroke initiative is launching a petition to call upon the World Health Organisation, its member states and health authorities worldwide to recognise atrial fibrillation as a risk factor for stroke and set clinical management targets that could save one million mothers, fathers, uncles, aunts and grandparents each year through better atrial fibrillation management, stroke prevention and education.

Roche will report new data on important progress for people with advanced cancers at ASCO 2012

2012-05-20T21:00:00Z

Roche (SIX: RO, ROG; OTCQX: RHHBY) will present important new data from studies of several of its cancer medicines at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1 to 5, 2012, in Chicago.

Amgen's BiTE® antibody blinatumomab (AMG 103) achieved high rate of complete response

2012-05-17T21:00:01Z

Amgen (NASDAQ:AMGN) announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) treated in the study.

Merck total revenues increase 3.2% to € 2.6 billion

2012-05-17T21:00:00Z

The Merck Group's first-quarter 2012 total revenues rose 3.2% to € 2,645 million compared to € 2,564 million in the first quarter of 2011. Sales for the Group increased 3.5% to € 2,564 million in first quarter compared to € 2,478 million in the year-ago quarter.

Pfizer provides topline results from Phase 3 study of Torisel®

2012-05-16T21:00:01Z

Pfizer Inc announced that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL® (temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT® (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.

GlaxoSmithKline to fully acquire Cellzome for £61 million

2012-05-15T21:00:01Z

GlaxoSmithKline plc (GSK) has entered into an agreement to acquire those shares it does not currently own in Cellzome, a leader in the development and advancement of proteomics technologies, for £61 million (US$99 million) in cash.

Bristol-Myers Squibb Foundation Announces $15 Million Expansion of Together on Diabetes® to China and India

2012-05-15T21:00:00Z

The Bristol-Myers Squibb Foundation today announced the expansion of its Together on Diabetes® initiative to China and India, pledging $15 million over five years to help these developing nations with rapidly growing numbers of type 2 diabetes patients.

Bristol-Myers Squibb and Tsinghua University Enter Strategic Partnership

2012-05-15T08:00:00Z

Bristol-Myers Squibb Company (NYSE:BMY) and Tsinghua University of Beijing, China, today announced the formation of a multi-year strategic partnership. Under the agreement, Bristol-Myers Squibb will fund research efforts at Tsinghua University's School of Life Sciences to identify and validate novel targets in oncology and immunoscience.

Statistically significant clinical phase III results of Lu AA21004

2012-05-14T13:00:00Z

H. Lundbeck A/S (Lundbeck) today announced positive top-line results from three recently completed phase III clinical studies of Lu AA21004, an investigational drug for the treatment of adults with major depressive disorder (MDD) using dosages from 10 to 20mg.

GSK commences tender offer to acquire Human Genome Sciences for US $13.00 per share in cash

2012-05-10T22:00:00Z

GlaxoSmithKline plc (LSE: GSK) today announced that it has commenced its previously announced tender offer to acquire all of the outstanding shares of Human Genome Sciences (NASDAQ: HGSI) for US$13.00 per share in cash.

Cancer Support Community launches national program to assist patients with cancer

2012-05-09T22:00:00Z

The Cancer Support Community (CSC) and the Amgen Foundation, today announced the launch of Open to Options", a program designed to bridge the communications gap between physicians and patients and inspire patient confidence in making treatment decisions.

Roche reports positive study of RoACTEMRA given by subcutaneous injection

2012-05-06T22:00:00Z

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy of the subcutaneous (SC) formulation of RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) 162mg weekly compared to 8 mg/kg RoACTEMRA intravenous (IV) formulation every 4 weeks.

Abbott to Acquire Action Pharma's Investigational Compound, AP214

2012-05-03T22:00:01Z

Abbott (NYSE: ABT) and Action Pharma A/S, a privately owned company, announced that they have entered into an agreement in which Abbott will acquire AP214 from Action Pharma. AP214 is in development to prevent acute kidney injury (AKI) associated with major cardiac surgery in patients at increased risk and has further potential in adjacent indications.